OncoSec Medical Selected to Present Phase II Data in Poster Highlights Session at 2014 ASCO Annual Meeting
April 22 2014 - 6:02AM
Business Wire
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its
ImmunoPulse DNA-based immunotherapy to treat solid tumors, will
present an update of data from their Phase 2 melanoma study at the
American Society of Clinical Oncology’s 50th Annual Meeting, taking
place May 30-June 3, 2014, at McCormick Place in Chicago, Illinois.
Additional details will be made available on or after May 14, 2014,
via the ASCO webpage: http://www.asco.org
“It is an honor to be selected to present in a Poster Highlights
Session at this year’s conference,” said Punit Dhillon, President
and CEO of OncoSec Medical. “We salute ASCO’s efforts to advance
oncology research and look forward to sharing data from our Phase 2
melanoma study with conference attendees and participants.”
Lead author, Dr. Adil Daud, will present an abstract titled,
“Systemic anti-tumor effect and clinical response in a phase 2
trial of intratumoral electroporation of plasmid interleukin-12 in
patients with advanced melanoma” (ASCO Abstract #9025), which
highlights unreleased data from the company’s Phase 2 study
investigating the use of ImmunoPulse in patients with metastatic
melanoma. The abstract will be part of the Poster Highlights
Session: Melanoma and Skin Cancers, taking place June 2, 2014. For
more information, please refer to the ASCO iPlanner:
https://iplanner.asco.org/AM2014
Said Robert Pierce, M.D., Chief Medical Officer, “We are excited
by the opportunity to present data from our Phase 2 study, which is
nearing completion. Our presentation will be one of those
highlighting the therapeutic potential of intralesional therapy and
the power of modulating the immune system in the treatment of
cancer.”
ASCO 2014 will bring together over 25,000 oncology professionals
from a wide range of specialties to explore this year’s theme –
“Science and Society”. Attendees will have access to cutting-edge
scientific presentations and comprehensive educational content that
reflect ASCO’s dedication to providing the highest-quality
resources in education, policy, the pioneering of clinical
research, and the advancement of care for patients with cancer.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing
its ImmunoPulse immunotherapy to treat solid tumors. OncoSec
Medical's core technology leverages a proprietary electroporation
platform to enhance the local delivery and uptake of
IL-12 and other DNA-based immune-modulating agents. Clinical
studies of ImmunoPulse have demonstrated an acceptable safety
profile and preliminary evidence of anti-tumor activity in the
treatment of various skin cancers, as well as the potential to
initiate a systemic immune response without the systemic toxicities
associated with other treatments. OncoSec's clinical programs
currently include three Phase 2 trials targeting metastatic
melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma
(http://clinicaltrials.gov/ct2/results?term=oncosec&Search=Search).
As the company continues to evaluate ImmunoPulse in these
indications, it is also investigating additional indications and
combination therapeutic approaches. For more information, please
visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
OncoSec Medical Inc.Investor Relations:Veronica Vallejo, CFO,
855-662-6732investors@oncosec.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2023 to Apr 2024